New pharmacological approaches for obesity management

  title={New pharmacological approaches for obesity management},
  author={Christian F. Rueda-Clausen and Raj S. Padwal and Arya M. Sharma},
  journal={Nature Reviews Endocrinology},
Obesity, which results from an imbalance between calorie intake and expenditure, now affects over 500 million individuals worldwide. Lifestyle and behavioural interventions aimed at reducing calorie intake and/or increasing energy expenditure have limited long-term effectiveness due to complex and persistent hormonal, metabolic and neurochemical adaptations that defend against weight loss and promote weight regain. Surgical treatments for obesity, although highly effective, are unavailable or… 

Pharmacotherapy for the treatment of obesity

Obesity medications: what does the future look like?

  • W. S. Butsch
  • Medicine, Biology
    Current opinion in endocrinology, diabetes, and obesity
  • 2015
Six US Food and Drug Administration-approved antiobesity medications, including two combination medications, will allow providers to tailor obesity treatment in combination with lifestyle modification for a great number of individuals with obesity.

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

The systematic review presented here focuses on naltrexone sustained- release/bupropion sustained-release combination (Contrave®) and concludes that its effectiveness in the treatment of obesity can be estimated as a placebo-subtracted weight loss of around 4.5%.

New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy

With differences in efficacy (higher for the topiramate–phentermine combination), both preparations are active in reducing appetite and body weight, as well as in improving comorbidities.


  • A. Garber
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2015
OBJECTIVE Type 2 diabetes and its associated complications place heavy burdens on affected individuals, their caregivers, and society. The prevalence of type 2 diabetes is increasing worldwide.

Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk

This review will outline the mechanisms of action of these newer generation weight management medications and their implications for both diabetes and cardiovascular risks.

Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment

The potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes are focused on.

Medical Management of Obesity

The genetic-environment combination is central to the genesis of obesity, and other factors considered to contribute to the obesity epidemic are use of drugs that have weight gain as a side effect, reduction in variability of ambient temperatures, sleep debt, and intrauterine and intergenerational effects.

Alternative Treatments for Weight Loss: Safety/Risks and Effectiveness of Anti-Obesity Medicinal Plants

Based on a review of the available literature, the consumption of recommended medicinal plants in a single form, and at an optimum dosage, could be a safe and effective complementary treatment for obesity.



Combination therapy with naltrexone and bupropion for obesity

When used in conjunction with diet and exercise, the naltrexone/bupropion combination may be a useful treatment option for obesity, especially for overweight and obese adults who report difficulty controlling eating behavior and their response to food cravings.

Rational Design of a Combination Medication for the Treatment of Obesity

Results supported the hypothesis that NAL, through blockade of β‐endorphin mediated POMC autoinhibition, prevents the classic weight loss plateau observed with monotherapies such as BUP.

Appetite regulation and weight control: the role of gut hormones

The central mechanisms involved in body weight regulation are discussed and a suite of well characterized and intensely investigated anorexigenic and orexigenic gut hormones are explored, their appetite-regulating capabilities, post-GI surgery physiology and emerging potential as anti-obesity therapeutics are reviewed.

Appetite suppressants. A review.

Of the compounds currently indicated for use in obesity, dexfenfluramine appears to have the most suitable pharmacological profile, although it should not be given to patients with a history of depression.

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

This article provides the first comprehensive meta-analysis of randomized clinical trials of medications for obesity, and no drug, or class of drugs, demonstrated clear superiority as an obesity medication.

Long-term persistence of hormonal adaptations to weight loss.

One year after initial weight reduction, levels of the circulating mediators of appetite that encourage weight regain after diet-induced weight loss do not revert to the levels recorded before weight loss.

[Drug treatment of obesity].

Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized clinical trials for sibutramine and orlistat, and rimonabant is expected to receive approval in 2005 or 2006.

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.

NB caused gradual sustained weight loss over 48 wk; NB32 and NB16 demonstrated greater weight loss in the intent-to-treat population due to lower attrition rates; further study is needed to demonstrate long-term efficacy and safety of NB.